Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Pharmaceutical composition comprising antibody composition which specifically binds to CCR4
US8980263B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8980263-B2 |
| Application number | US-201313914027-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 10, 2013 |
| Priority date | Sep 10, 2009 |
| Publication date | Mar 17, 2015 |
| Grant date | Mar 17, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A pharmaceutical composition, comprising an antibody composition which specifically binds to human CC chemokine receptor 4 (hereinafter also referred to as CCR4) and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament are required. The present invention can provide a pharmaceutical composition comprising a recombinant antibody against CCR4 and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating a T-cell lymphoma that expresses human CC chemokine receptor 4 (CCR4), comprising administering mLSG15 therapy and a recombinant antibody which specifically binds to human CCR4, to a human in need thereof, wherein the mLSG15 therapy is a combination of vincristine, cyclophosphamide, doxorubicin, prednisolone, ranimustine, vindesine, etoposide, carboplatin, cytarabine, and methotrexate. 2. The method according to clai…
Assignees
Inventors
Classifications
- A61K39/3955Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8980263B2 cover?
- A pharmaceutical composition, comprising an antibody composition which specifically binds to human CC chemokine receptor 4 (hereinafter also referred to as CCR4) and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament are required. The present invention can provide a pharmaceutical composit…
- Who is the assignee on this patent?
- Kyowa Hakko Kirin Co Ltd, Kyowa Hakko Kirin Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K39/3955. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).